Diabetes drug company trial hitch

Shares in diabetes drug company Biodel have fallen considerably following questionable results in a late-stage human drug trial for a new type of diabetes medication.
The pharmaceutical company submitted two sets of results for diabetes drug VIAject at a conference in Romen, and one was found to have questionable results. VIAject was compared with Humulin (Eli Lilly) to assess whether the drug stabilised blood sugar and reduced weight gain amongst people with type 2 diabetes .
The team conducted the trials in India, the United Stated and Germany – but excluded the data from the type 1 diabetes study in India. The company are understood to be investigating the anomalies and submitting the data to the FDA. How the situation resolves remains to be seen.